The nasal vaccine against COVID-19

iNCOVACC is a novel adenovirus vectored, intranasal vaccine for COVID-19. It has various advantages over injectable vaccines. Here are a few of them.

The two-drop nasal vaccine, iNCOVACC is manufactured by Bharat Biotech, India. It is a novel adenovirus vectored, intranasal vaccine for COVID-19 that can stimulate a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses. 

How does it work?

The nasal vaccine is delivered through the nose or mouth. It is expected to work on the mucosal lining. Thus, the nasal vaccine prompts an immune response at the entry points of the virus which is mostly the nose and the mouth. This prevents infection at the entry point itself thereby protecting against disease, infection, and transmission. It is referred to as sterilizing immunity. Many studies have found that nasal delivery of vaccines is capable of creating a strong immune response.

Mice, Hamsters and macaques were immunized with a single dose of ChAd-SARS-CoV-2-S conferred superior protection against the SARS-CoV-2 challenge. Post-challenge with SARS-CoV-2, viral clearance was observed in both lower and upper airways in all these animal models.

Nasal vaccines v/s Injectable vaccines

Nasal vaccines have a proven benefit over injectable vaccines. In the third phase of the clinical trial which was done on 3,000 participants, iNCOVACC showed good immunity with 2 doses given 4 weeks apart.

Advantages of the nasal vaccine

  • An immune response at the site of infection is essential for blocking both infection and transmission of COVID-19.
  • Non-invasive, Needle-free
  • Ease of administration – does not require trained healthcare workers
  • Elimination of needle-associated risks (injuries and infections)
  • High compliance

Nasal vaccine composition

0.5 ml of this nasal vaccine contains NLT 5X10 particles per mL ChAd36-SARS-CoV-S COVID-19 virus (recombinant) including excipients such as Tris (pH 7.4), Sodium Chloride, Magnesium Chloride, Glycerol, Polysorbate- 80.

Those who have taken Covishield and Covaxin can take the nasal vaccine as a heterologous booster dose. In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series.

The nasal vaccine as a booster dose and not the fourth dose after the booster shot

The nasal vaccine is recommended as a first booster and cannot be administered after one has taken the booster or the precautionary dose. This is because by repeatedly immunizing with a particular type of antigen, the body stops responding or responds poorly. Therefore, taking the nasal vaccine as the fourth dose after taking the booster dose is of no value.

Tags : #COVID19 #Nasalvaccine #Vaccination #VaccineforCOVID19 #iNCOVACC #MadeinIndiavaccine #NasalvaccineforCOVID19 #Medicircle #SmitaKumar

About the Author

Renu Gupta

With a background in Pharmacy which is the clinical health science that links medical science with chemistry, I had the desire to mix creativity to these fields. Medicircle provides me an avenue to apply my training in science and interest in creativity together.

Related Stories

Loading Please wait...


Trending Now

Parental tips for keeping teens safe onlineFebruary 08, 2023
The Symptoms and Causes of Anorexia NervosaFebruary 08, 2023
Pervez Musharraf President of Pakistan died of Amyloidosis, a rare diseaseFebruary 07, 2023
National AIDS Control Program – Importance of knowing HIV statusFebruary 06, 2023
FGM : Let's End the practice that hurts girls and womenFebruary 06, 2023
World Cancer Day - Most prominent cancers of IndiaFebruary 04, 2023
World Cancer Day - Never Give up the HopeFebruary 04, 2023
Salt - Effects of Consuming too much SaltFebruary 03, 2023
India’s mission of eliminating dog-mediated rabies by 2030February 03, 2023
Climate change and healthFebruary 02, 2023
Rheumatoid Arthritis Awareness Day: Let's Create AwarenessFebruary 02, 2023
Importance of early diagnosis and cancer screeningFebruary 01, 2023
Union Budget 2023-2024: What's for Healthcare?February 01, 2023
Nourish You has raised $2million to Invest in R&D and Strengthen its Market Presence.February 01, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
World Leprosy Day 2023 – Act now, End LeprosyJanuary 30, 2023
The Warrior Expedition 32/26: A Mission to Encourage Youths to join Indian ForcesJanuary 30, 2023
Mental health – What’s normal and what’s abnormalJanuary 30, 2023
Big Data in Healthcare and Its BenefitsJanuary 27, 2023